Evoke Pharma (EVOK) has released an update to notify the public and investors about an entry into a material definitive agreement.
Evoke Pharma, Inc. has partnered with underwriters to sell over 5 million common stock units at $0.68 each and nearly 6 million pre-funded warrant units at just under $0.68 each. These units include a mix of shares and warrants with varying expiration dates and exercise prices. The deal, which is aimed to net the company around $6.1 million after costs and is contingent on standard closing conditions, is scheduled to complete around February 13, 2024. This public offering is part of a pre-approved registration with the SEC, positioned to attract investors looking for diverse options in the pharma sector.
For further insights into EVOK stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
